<DOC>
	<DOCNO>NCT00434174</DOCNO>
	<brief_summary>This study evaluate safety everolimus combination pemetrexed used treatment patient non small cell lung cancer .</brief_summary>
	<brief_title>Safety Everolimus Pemetrexed Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion criterion : Lung cancer Only one prior regimen chemotherapy treatment non small cell lung cancer Adequate bone marrow function Adequate liver function Adequate renal function Negative serum pregnancy test Exclusion criterion : History another primary malignancy last 5 year Having recently receive investigational drug Having recently receive major surgery wide field radiotherapy Chronic treatment immunosuppressive therapy , steroid liver enzyme modulators Severe uncontrolled medical condition Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>RAD001</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Afinitor</keyword>
	<keyword>Pemetrexed</keyword>
</DOC>